ConcertAI

Overview

ConcertAI is a Cambridge, MA-based oncology AI and real-world data (RWD) company providing Data-as-a-Service and AI Software-as-a-Service to life sciences, healthcare providers, and medical societies. Originally spun out of SymphonyAI Group (now SAIGroup) in 2017-2018, ConcertAI remains a portfolio company of SAIGroup, the private AI conglomerate founded by Dr. Romesh Wadhwani; SAIGroup is the majority owner alongside minority investors Sixth Street, Declaration Partners, and Maverick Ventures. ConcertAI is anchored by ASCO’s CancerLinQ network with 9M+ de-identified cancer patient records and reports serving 75% of the top 30 life sciences companies.

ConcertAI is an oncology specialist, not a broad cross-therapy RWD platform like IQVIA, Komodo, or HealthVerity. Its differentiated assets are the CancerLinQ clinico-genomic dataset and the multi-modal data layer added via TeraRecon imaging AI. Outside oncology and hematology, manufacturers should evaluate a broader RWD vendor; for oncology label expansion, comparator arm, and real-world endpoint work, ConcertAI is on the shortlist.

Real-World Evidence Capability Model

The framework below standardizes how Rx Almanac evaluates real-world-evidence capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, ConcertAI is evaluated as Cambridge, MA-based oncology AI and real-world data (RWD) company providing Data-as-a-Service and AI Software-as-a-Service to life sciences, healthcare providers, and medical societies.

Capability	Buyer should compare	ConcertAI readout
Data assets and linkage coverage	Claims, EHR, registry, lab, mortality, genomic, provider, and patient-level linkage breadth.	Core coverage workflow. CancerLinQ network with 9M+ de-identified cancer patient records; clinico-genomic dataset of approximately 500K linked patients; partnerships with Caris, Guardant, NeoGenomics, and Foundation Medicine extend the genomic layer.
Study design and causal inference	Protocol development, statistical methods, bias control, synthetic/external controls, and reproducibility.	Study-design work. Synthetic and external-control work is a documented use case for the CancerLinQ dataset; confirm specific methods documentation and publication track record in the target tumor type.
Regulatory, HTA, and payer evidence packages	FDA, EMA, NICE/HTA, payer value dossiers, label expansion, and post-market evidence use cases.	Core regulatory evidence. FDA CDER five-year collaborative research agreement; ASCO CancerLinQ provenance supports regulatory-grade oncology RWE work.
Oncology, rare disease, and specialty depth	Fit for small populations, biomarkers, longitudinal oncology records, rare-disease cohorts, and specialty-drug endpoints.	Core oncology and rare-disease evidence. Oncology and hematology are the headline therapy fit; ConcertAI is purpose-built for biomarker-driven cohorts, longitudinal oncology records, and cell and gene therapy endpoints.
Analytics platform and self-service workflow	User-facing software, cohort builders, query tools, dashboards, and analyst service model.	Core analytics workflow. CARAai oncology-tuned AI/LLM platform with agentic capabilities; TeraRecon imaging AI enables multi-modal data linkage; NVIDIA NIM microservices integration extends compute scale.
Privacy, governance, and refresh cadence	HIPAA controls, de-identification, data rights, governance, update frequency, and auditability.	Confirm governance control in the RFP. Confirm de-identification standards, refresh cadence on CancerLinQ updates, data-use rights for partner-sourced genomic data, and audit-trail outputs.

Buyer Fit

• Include when: Oncology and hematology manufacturers needing decision-grade RWE for label expansion, comparator arms, post-marketing studies, or HTA submissions in tumor types with limited prospective data.
• Best-fit buyers: Small molecule, biologics, cell therapy, and gene therapy oncology programs; manufacturers needing clinico-genomic linkage across CancerLinQ plus partner genomic datasets; provider-engaged research where CancerLinQ site relationships matter.
• Less ideal fit: Cross-therapy RWD use cases outside oncology and hematology; manufacturers needing broad claims and pharmacy benefit data across all therapy areas.
• Commercial fit: Subscription pricing for software and DaaS access; project-based scoping for custom studies; confirm modular versus bundled access and how cohort-refresh cadence aligns with launch milestones.
• Operating diligence: Data provenance and de-identification standards, refresh cadence, partner-data-use rights (especially Foundation Medicine, which shares a Roche parent with Flatiron), protocol transparency, and whether work is software self-service or vendor-led services.

Differentiators

• CancerLinQ anchor: Exclusive ASCO partnership for the CancerLinQ oncology RWD network; 9M+ de-identified cancer patient records and 2,000+ healthcare provider and research sites globally.
• Clinico-genomic dataset: Approximately 500K linked patients across CancerLinQ plus Caris, Guardant, NeoGenomics, and Foundation Medicine partnerships; among the largest linked oncology clinico-genomic assets.
• CARAai oncology AI platform: Oncology-tuned AI/LLM with agentic capabilities; NVIDIA NIM microservices integration extends compute scale for large clinical simulations.
• TeraRecon imaging AI: Multi-modal data linkage extends RWD beyond EHR-only competitors; 5.5M multi-modal oncology RWD records reported.
• SAIGroup ownership stability: Single-founder-owner structure with up to $1B in committed personal capital from Dr. Romesh Wadhwani provides unusual strategic patience versus VC-backed RWE peers.

RFP Questions

• Which CancerLinQ and partner genomic data sources are native, licensed, or partner-dependent for the target tumor type and biomarker profile?
• What methods documentation, publication record, and regulatory references exist for similar label expansion, external-control, or RWE studies in the target therapy area?
• How quickly can cohorts refresh after launch, new indication, or major label update?
• Which work is software-enabled self-service via CARAai versus vendor-led services from the analyst team?
• How does ConcertAI manage potential conflicts where partner data sources (e.g., Foundation Medicine) share a corporate parent with a direct competitor (Flatiron Health / Roche)?
• What de-identification, audit-trail, and data-use governance applies to multi-modal data (EHR plus imaging plus genomics)?
• Which provider sites in the CancerLinQ network are active in the target therapy area, and what site engagement is included?

Recent Activity

• 2026-01: Foundation Medicine partnership announced; combined data assets to create a large-scale clinico-genomic oncology dataset (note: Foundation Medicine is a Roche subsidiary, same parent as Flatiron Health competitor).
• 2025-10: Dr. Shaalan Beg appointed CMO Oncology.
• 2025-09: Casey Graves appointed GM Clinical Solutions, a newly created role overseeing RWE, clinical trials, and CancerLinQ.
• 2025-08: Michael Myshrall appointed CFO.
• 2025-05: Eron Kelly appointed CEO (prior Inovalon, AWS, Microsoft).
• 2024-12 / 2025-01: CTO-H launched.
• 2024-06: NVIDIA collaboration for NIM microservices integration enabling large-scale clinical simulations.
• 2024-01: CARAai platform launched at JPM Healthcare Conference.